Importantly, the combination of SA‐TL with anti‐PD‐L1 antibody resulted in an obvious increase in M1‐like macrophages (CD11b+F4/80+MHCII+) as well as CD8+IFNγ+ T cells, leading to superior antitumor efficacy compared with PD‐L1 antibody or SA‐TL monotherapy in subcutaneous MC38 and B16F10 tumor models.[70] This study underscores the promise of DC‐targeted STING agonists to synergize with PD‐L1 blockade, providing a novel strategy to overcome immune resistance and improve antitumor immune responses. This evidence concerns the gene STING1 and neoplasm.